Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Sovleplenib - HUTCHMED

Next Previous
Drug Profile

Sovleplenib - HUTCHMED

Alternative Names: HMPL-523; HMPL-523 acetate

Latest Information Update: 27 Feb 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Hutchison MediPharma
  • Developer Hutchison MediPharma; HUTCHMED
  • Class Amines; Anti-inflammatories; Antianaemics; Antineoplastics; Antirheumatics; Morpholines; Piperidines; Pyrazines; Pyridones; Small molecules; Sulfones
  • Mechanism of Action Immunomodulators; Syk kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preregistration Idiopathic thrombocytopenic purpura
  • Phase II/III Autoimmune haemolytic anaemia
  • Phase I B-cell lymphoma; Haematological malignancies; Lymphoma; Unspecified
  • Discontinued Lupus vulgaris; Multiple sclerosis; Rheumatoid arthritis

Most Recent Events

  • 06 Feb 2026 Hutchmed completes a phase I pharmacokinetics trial (In volunteers) in China (PO, Tablet) (NCT07348133)
  • 07 Jan 2026 HUTCHMED announces intention to submit NDA to China National Medical Products Administration for Sovleplenib for Autoimmune haemolytic anaemia in the first half of 2026 (PO)
  • 10 Dec 2025 Hutchmed initiates enrollment in a phase I pharmacokinetics trial (In volunteers) in China (PO, Tablet) (NCT07348133)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top